ICC for Sanofi Pasteur's TravelWise Program
Pharmaceutical Executive
The last thing on the mind of an adventurous traveler is a pre-trip immunization, which, consequently, is not top-of-mind for their healthcare providers, either.
POSTCARDS
ICC
BRAND TravelWise Program CLIENT Sanofi Pasteur AT RIGHT: Chet Moss, executive vice president, chief creative officer NOT PICTURED: Karen Neale, writer; Suzanne Elward, art director
The last thing on the mind of an adventurous traveler is a pre-trip immunization, which, consequently, is not top-of-mind for their healthcare providers, either. The work of ICC for Sanofi Pasteur helped deepen the necessary dialogue and increase awareness of the need for vaccination when traveling to many far-off lands through the use of classic souvenir postcards from more than 50 years ago.
The campaign embraced multiple tactics all predicated on the visual parody of the postcards. "The marketing challenge was to get people to pay attention to these insidious diseases lurking in foreign lands, and to ramp up the discussion between healthcare provider and traveler," notes Chet Moss, executive vice president, chief creative officer of ICC. "It was done in a warm and approachable way."
Each card was driven by the same call to action: "Be Aware...Prepare!" Yet each advertisement features a surprising twist. For instance, expecting to see Yellowstone National Park on the postcard, the airbrushed message reveals another possible destination: Yellow Fever. "You can't help but pay attention," says Moss. "You take common ground and put a twist on it...and that's what great advertising is about."
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
